Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio, or simply access the investment bank-grade financial models and research. I hope to see you there.Merck & Co., Inc. (NYSE: MRK ) will report its Q3 earnings next Thursday, 31st October. I covered the company shortly before Q2 earnings, assigning the stock a "Hold" rati ...